RESULTS
Salient demographic patient pre- and post-treatment parameters are depicted in Table 1(a) and 1(b) respectively, the pre-treatment data was comparable in most parameters with the exception of nocturia (p<0.001) and IPSS (SS), p = 0.001. In terms of the post treatment data (Table 1b) that there was statistically significant improvement of the OABS score (primary outcome parameter) in the intervention group (Mean difference -5.62 vs -2.22p< 0.001). Similar improvements were seen in most secondary outcome parameters [mean change in voiding episode/night, IPSS, IPSS-S, OABS-SS, voided volume/micturition, Qmax and QOL (p<0.001)]. As opposed to other published studies depicting acute urinary retention (AUR) as a major complication of Mirabegron intake, our study did not reveal any significant increase in PVR (p=0.136) nor any Acute Urinary Retention (AUR)in the intervention arm.Three of 80(3.8%), 2 and 1 in groups I and II respectively) had TEAE (tachycardia/headache) which were minor self-limiting and managed symptomatically without drug discontinuity. There was complete compliance to the administered therapy.